Beyond the Blood Spot: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease
Presented on .
Newborn screening began in the United States in the 1960s to test for medical conditions that may not be apparent just by looking at a baby. Finding these conditions soon after birth can help prevent certain serious problems, such as brain damage, organ damage, and even death. The traditional method of newborn screening is bloodspot testing, wherein blood is sent to a lab to be screened for a number of conditions. There is also a newer paradigm of point-of-care newborn screening to test for hearing loss and critical congenital heart defects, conditions that are not identifiable through blood tests.
Both traditional bloodspot screening and the newer point-of-care screening tests share the goals of making sure that newborns are tested for certain potentially life-threatening conditions, and ensuring that providers follow up based on test results. The newer tests, however, do pose some unique challenges for public health. Because these tests take place in the health care setting rather than in a lab, it is difficult to standardize both the implementation of the tests and reporting of the test results. Newborn screening is also mandated by each individual state, so tests required in some states may not be in others.
In this session of Public Health Grand Rounds, you will hear how some states have implemented point-of-care newborn screening and what challenges they have faced in standardizing these tests and tracking test results. Speakers will also discuss how public health partners at all levels can work toward ensuring that every baby is screened.
Newborn screening began in the United States in the 1960s to test for medical conditions that may not be apparent just by looking at a baby. Finding these conditions soon after birth can help prevent certain serious problems, such as brain damage, organ damage, and even death.
- Stuart K. Shapira, MD, PhD
- Associate Director for Science
National Center on Birth Defects and Developmental Disabilities, CDC
- Marci K. Sontag, PhD
- Associate Professor of Epidemiology
University of Colorado Anschutz Medical Campus
- Kim Van Naarden Braun, PhD
- Epidemiologist, Division of Family Health Services
New Jersey Department of Health
- Craig A. Mason, PhD
- Professor of Education and Applied Quantitative Methods
University of Maine
- John Iskander, MD, MPH
- Scientific Director
- Phoebe Thorpe, MD, MPH
- Deputy Scientific Director
- Susan Laird, MSN, RN
- Communications Director
Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!
Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!Sign Up
More than 4 million newborns in the US are screened yearly for hearing loss and certain disorders. Learn how newborn screening provides an opportunity for reductions in morbidity and mortality while reducing health care costs associated with treatment of lifelong debilitating conditions.
Neonatal Abstinence Syndrome (NAS) is a growing problem in the United States. NAS occurs when newborn babies experience withdrawal after being exposed to drugs in the womb. NAS can cause low birth weight and other complications leading to prolonged hospitalization.